YDES
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is completely detached from current revenue generation.
- P/B ratio is near 1.0
- P/S ratio of 724.75 is unsustainable
- No P/E or PEG available due to losses
Growth is present but not translating into operational efficiency.
- High YoY revenue growth (95.6%)
- Operating margins are deeply negative
- High cash burn implied by margins
Consistent and accelerating downward price trajectory.
- 1Y return of -60.7%
- 6M return of -70.2%
- 1M return of -32.1%
Strong liquidity provides a runway, but fundamental operational health is poor.
- Zero debt
- Very high current and quick ratios
- Piotroski F-Score of 3/9 (Weak)
- Negative ROE and ROA
Typical for early-stage biotech; no income component.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for YDES and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
YDES
YD Bio Ltd
Primary
|
-60.7% | -60.7% | -60.7% | -70.2% | -32.1% | -1.0% |
|
SRZN
Surrozen, Inc.
Peer
|
-78.7% | +192.2% | +223.8% | +132.4% | +22.9% | +11.9% |
|
PBYI
Puma Biotechnology, Inc.
Peer
|
-24.3% | +142.1% | +151.4% | +33.8% | +17.9% | -7.2% |
|
NAGE
Niagen Bioscience, Inc.
Peer
|
-45.0% | +228.0% | -23.6% | -37.2% | -2.3% | +4.9% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q2 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
YDES
YD Bio Ltd
|
BEARISH | $369.88M | - | -42.7% | -276.6% | $5.25 | |
|
SRZN
Surrozen, Inc.
|
BEARISH | $371.23M | - | -% | -% | $31.56 | Compare |
|
PBYI
Puma Biotechnology, Inc.
|
BEARISH | $368.35M | 11.87 | 28.0% | 13.6% | $7.24 | Compare |
|
NAGE
Niagen Bioscience, Inc.
|
NEUTRAL | $375.58M | 23.45 | 28.3% | 13.4% | $4.69 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
Past News Coverage
Recent headlines mentioning YDES from our newsroom.